# XTL Biopharmaceuticals Ltd: overview

XTLB · Nasdaq · CIK 1023549 · [Healthcare](/sectors/healthcare.md)

Pages: [Overview](/companies/xtlb.md) · [Financials](/companies/xtlb/financials.md) · [Filings](/companies/xtlb/filings.md) · [Insiders](/companies/xtlb/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

Not reported.

## Last five fiscal years

| Line item | Unit | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY (2023-12-31) | FY2024 (2024-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | [451](/filings/0001213900-25-037590.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | [0.7%](/filings/0001213900-25-037590.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | [(481.6%)](/filings/0001213900-25-037590.md) |
| Net margin | % | not reported | not reported | not reported | not reported | [(227.7%)](/filings/0001213900-25-037590.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001213900-23-021869.md) | [0.00](/filings/0001213900-23-021869.md) | [(0.00)](/filings/0001213900-25-037590.md) | [(0.00)](/filings/0001213900-25-037590.md) | [(0.00)](/filings/0001213900-25-037590.md) |
| Free cash flow | $k | [(851)](/filings/0001213900-23-021869.md) | not reported | not reported | not reported | [(1,672)](/filings/0001213900-25-037590.md) |

- Revenue. XBRL Revenue: ifrs-full:Revenue.
- Gross margin (gross profit / revenue). XBRL Gross profit: ifrs-full:GrossProfit; Revenue: ifrs-full:Revenue.
- Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue.
- Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue.
- Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xtlb/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $17.0k | 6,228 |  | Added +241 |
| [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $3.3k | 1,213 |  | Reduced −2,175 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $341 | 125 |  | New +125 |

## Recent filings

[All 376 filings](/companies/xtlb/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 20:05 ET | [6-K](/filings/0001213900-26-109415.md) | Report of a foreign private issuer, period 2026-10-14 | 0001213900-26-109415 |
| 2026-08-05 | 20:21 ET | [6-K](/filings/0001213900-26-085693.md) | Report of a foreign private issuer, period 2026-08-05 | 0001213900-26-085693 |
| 2026-07-21 | 20:05 ET | [6-K](/filings/0001213900-26-080006.md) | Report of a foreign private issuer, period 2026-07-21 | 0001213900-26-080006 |
| 2026-06-30 | 21:24 ET | [20-F](/filings/0001213900-26-073831.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001213900-26-073831 |
| 2026-06-30 | 21:16 ET | [6-K](/filings/0001213900-26-073813.md) | Report of a foreign private issuer, period 2026-06-30 | 0001213900-26-073813 |
| 2026-06-29 | 20:39 ET | [6-K](/filings/0001213900-26-073158.md) | Report of a foreign private issuer, period 2026-06-29 | 0001213900-26-073158 |
| 2026-06-23 | 23:23 ET | [6-K](/filings/0001213900-26-070771.md) | Report of a foreign private issuer, period 2026-06-22 | 0001213900-26-070771 |
| 2026-05-22 | 20:11 ET | [6-K](/filings/0001213900-26-060565.md) | Report of a foreign private issuer, period 2026-05-22 | 0001213900-26-060565 |
| 2026-05-15 | 21:09 ET | [6-K](/filings/0001213900-26-057942.md) | Report of a foreign private issuer, period 2026-05-15 | 0001213900-26-057942 |
| 2026-05-07 | 12:10 ET | [6-K](/filings/0001213900-26-053067.md) | Report of a foreign private issuer, period 2026-05-07 | 0001213900-26-053067 |

## Latest annual report

[Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-073831.md), filed Jun 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1023549
- Tickers: XTLB
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: L3
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.